XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-term debt (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Apr. 01, 2024
Apr. 01, 2023
Jan. 29, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
2021 Amended Facility                
Long-term Debt                
Proceed from drew down     $ 35.0          
2018 and 2021 Amended Facility                
Long-term Debt                
Foreign currency loss       $ 6.6 $ 1.8 $ 15.0 $ 4.0  
Interest expense recorded         $ 1.9   $ 5.2  
Restated Facility 2021                
Long-term Debt                
Outstanding debt       $ 100.0   100.0    
Proceed from drew down           $ 30.0    
Interest rate (as a percent)       7.95%   7.95%    
Back-end fee (as a percent)           4.85%    
Back-end fees due       $ 2.5   $ 2.5    
Amortized cost net of discount and debt issuance costs       103.3   103.3   $ 101.6
Interest expense recorded       3.0   8.1    
Restated Facility 2021 | Tranche One                
Long-term Debt                
Outstanding debt       $ 70.0   $ 70.0    
Restated Facility 2021 | Prime Rate                
Long-term Debt                
Variable interest rate basis           7.95%    
Discount rate (as a percent)       3.25%   3.25%    
Venture debt loan facility | Restated Facility 2021                
Long-term Debt                
Minimum cash and cash equivalents in U.S. bank accounts           65.00% 100.00%  
Assets pledged to secure facilities by directly or indirectly           $ 638.2    
Assets not being pledged to secure facilities by directly or indirectly           75.3    
Venture debt loan facility | Restated Facility 2021 | Corlieve Therapeutics SAS                
Long-term Debt                
Assets not being pledged to secure facilities by directly or indirectly           $ 80.2    
Subsequent events. | Venture debt loan facility | Restated Facility 2021                
Long-term Debt                
Minimum cash and cash equivalents in U.S. bank accounts 30.00% 50.00%